fasudil has been researched along with Anterior Choroidal Artery Infarction in 12 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the effect of the novel intracellular calcium antagonist fasudil hydrochloride, cerebral blood flow (CBF) was measured quantitatively with positron emission tomography following the intravenous administration of fasudil in five patients with chronic cerebral infarction." | 9.07 | Effects of fasudil hydrochloride on cerebral blood flow in patients with chronic cerebral infarction. ( Hatazawa, J; Hirata, Y; Kanno, I; Kondoh, Y; Nagata, K; Satoh, Y; Shishido, F; Watahiki, Y; Yokoyama, E; Yuya, H, 1993) |
| "Fasudil greatly reduces the occurrence of CVS and cerebral infarction in SAH patients, significantly improves the clinical outcomes of the patients (as assessed by the Glasgow Outcome Scale)." | 8.88 | Systematic assessment and meta-analysis of the efficacy and safety of fasudil in the treatment of cerebral vasospasm in patients with subarachnoid hemorrhage. ( He, GH; Liu, GJ; Liu, Y; Luo, GJ; Wang, XL; Wang, YF; Wang, ZJ; Xu, LL; Zeng, YJ, 2012) |
| "Four groups of rats were randomized as follows: Cerebral ischemia-reperfusion (IR), Fasudil, CIMT and CIMT + Fasudil." | 8.12 | Combination of constraint-induced movement therapy with fasudil amplifies neurogenesis after focal cerebral ischemia/reperfusion in rats. ( Guo, Y; Zhai, Z, 2022) |
| "Fasudil were added in 18 (38." | 5.91 | Real-world data of clazosentan in combination therapy for aneurysmal subarachnoid hemorrhage: a multicenter retrospective cohort study. ( Araki, Y; Asai, T; Fukui, T; Koketsu, N; Muraoka, S; Nishizawa, T; Ota, S; Saito, R; Shimato, S, 2023) |
| "significantly reduced cerebral infarction." | 5.37 | Fasudil and ozagrel in combination show neuroprotective effects on cerebral infarction after murine middle cerebral artery occlusion. ( Hamanaka, J; Hara, H; Hozumi, I; Inuzuka, T; Kawasaki, K; Koumura, A; Shimazawa, M; Tsuruma, K, 2011) |
| "To evaluate the effect of the novel intracellular calcium antagonist fasudil hydrochloride, cerebral blood flow (CBF) was measured quantitatively with positron emission tomography following the intravenous administration of fasudil in five patients with chronic cerebral infarction." | 5.07 | Effects of fasudil hydrochloride on cerebral blood flow in patients with chronic cerebral infarction. ( Hatazawa, J; Hirata, Y; Kanno, I; Kondoh, Y; Nagata, K; Satoh, Y; Shishido, F; Watahiki, Y; Yokoyama, E; Yuya, H, 1993) |
| "Fasudil greatly reduces the occurrence of CVS and cerebral infarction in SAH patients, significantly improves the clinical outcomes of the patients (as assessed by the Glasgow Outcome Scale)." | 4.88 | Systematic assessment and meta-analysis of the efficacy and safety of fasudil in the treatment of cerebral vasospasm in patients with subarachnoid hemorrhage. ( He, GH; Liu, GJ; Liu, Y; Luo, GJ; Wang, XL; Wang, YF; Wang, ZJ; Xu, LL; Zeng, YJ, 2012) |
| "Four groups of rats were randomized as follows: Cerebral ischemia-reperfusion (IR), Fasudil, CIMT and CIMT + Fasudil." | 4.12 | Combination of constraint-induced movement therapy with fasudil amplifies neurogenesis after focal cerebral ischemia/reperfusion in rats. ( Guo, Y; Zhai, Z, 2022) |
| "Fasudil were added in 18 (38." | 1.91 | Real-world data of clazosentan in combination therapy for aneurysmal subarachnoid hemorrhage: a multicenter retrospective cohort study. ( Araki, Y; Asai, T; Fukui, T; Koketsu, N; Muraoka, S; Nishizawa, T; Ota, S; Saito, R; Shimato, S, 2023) |
| "significantly reduced cerebral infarction." | 1.37 | Fasudil and ozagrel in combination show neuroprotective effects on cerebral infarction after murine middle cerebral artery occlusion. ( Hamanaka, J; Hara, H; Hozumi, I; Inuzuka, T; Kawasaki, K; Koumura, A; Shimazawa, M; Tsuruma, K, 2011) |
| "Evidence that Rho-kinase is involved in cerebral infarction has accumulated." | 1.35 | Demonstration of elevation and localization of Rho-kinase activity in the brain of a rat model of cerebral infarction. ( Asano, T; Hattori, T; Ikegaki, I; Kawasaki, K; Sasaki, Y; Satoh, S; Seto, M; Tawara, S; Toshima, Y; Yano, K, 2008) |
| "Cerebral ischemia was induced in rats by injecting 150 mug of sodium laurate into the left internal carotid artery on day 1." | 1.35 | Wide therapeutic time window for Rho-kinase inhibition therapy in ischemic brain damage in a rat cerebral thrombosis model. ( Asano, T; Hitomi, A; Ikegaki, I; Satoh, S; Seto, M; Toshima, Y, 2008) |
| "Pharmacological treatment for cerebral ischemia cannot attain sufficiently high concentrations of the drugs in the cerebrospinal fluid (CSF) without precipitating systemic side effects." | 1.31 | Neuroprotection by intrathecal application of liposome-entrapped fasudil in a rat model of ischemia. ( Allen, TM; Ishida, T; Kirchmeier, MJ; Shuaib, A; Takanashi, Y, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (25.00) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 3 (25.00) | 24.3611 |
| 2020's | 2 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Muraoka, S | 1 |
| Asai, T | 1 |
| Fukui, T | 1 |
| Ota, S | 1 |
| Shimato, S | 1 |
| Koketsu, N | 1 |
| Nishizawa, T | 1 |
| Araki, Y | 1 |
| Saito, R | 1 |
| Zhai, Z | 1 |
| Guo, Y | 1 |
| Gibson, CL | 1 |
| Srivastava, K | 1 |
| Sprigg, N | 1 |
| Bath, PM | 1 |
| Bayraktutan, U | 1 |
| Yano, K | 1 |
| Kawasaki, K | 2 |
| Hattori, T | 1 |
| Tawara, S | 1 |
| Toshima, Y | 2 |
| Ikegaki, I | 2 |
| Sasaki, Y | 1 |
| Satoh, S | 2 |
| Asano, T | 2 |
| Seto, M | 2 |
| Koumura, A | 1 |
| Hamanaka, J | 1 |
| Tsuruma, K | 1 |
| Shimazawa, M | 1 |
| Hozumi, I | 1 |
| Inuzuka, T | 1 |
| Hara, H | 1 |
| Liu, GJ | 1 |
| Wang, ZJ | 1 |
| Wang, YF | 1 |
| Xu, LL | 1 |
| Wang, XL | 1 |
| Liu, Y | 1 |
| Luo, GJ | 1 |
| He, GH | 1 |
| Zeng, YJ | 1 |
| Kitazono, T | 1 |
| Hitomi, A | 1 |
| Ohtaki, M | 1 |
| Tranmer, B | 1 |
| Nagata, K | 1 |
| Kondoh, Y | 1 |
| Satoh, Y | 1 |
| Watahiki, Y | 1 |
| Yokoyama, E | 1 |
| Yuya, H | 1 |
| Hirata, Y | 1 |
| Shishido, F | 1 |
| Hatazawa, J | 1 |
| Kanno, I | 1 |
| Takanashi, Y | 1 |
| Ishida, T | 1 |
| Kirchmeier, MJ | 1 |
| Shuaib, A | 1 |
| Allen, TM | 1 |
| Shibuya, M | 1 |
| Suzuki, Y | 1 |
| Sugita, K | 1 |
| Saito, I | 1 |
| Sasaki, T | 1 |
| Takakura, K | 1 |
| Nagata, I | 1 |
| Kikuchi, H | 1 |
| Takemae, T | 1 |
| Hidaka, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Cilostazol-Nimodipine Combined Therapy on Delayed Cerebral Ischemia After Aneurysmal Subarachnoid Hemorrhage (aSAH): A Prospective, Randomized, Double-Blinded, Placebo-Controlled Trial[NCT04148105] | Phase 4 | 120 participants (Anticipated) | Interventional | 2019-11-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for fasudil and Anterior Choroidal Artery Infarction
| Article | Year |
|---|---|
Systematic assessment and meta-analysis of the efficacy and safety of fasudil in the treatment of cerebral vasospasm in patients with subarachnoid hemorrhage.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Cerebral Infarction; Humans; Middle Aged; Prot | 2012 |
[Fasudil hydrochloride].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cerebral Infarction; Humans; Protein Kinase | 2006 |
2 trials available for fasudil and Anterior Choroidal Artery Infarction
| Article | Year |
|---|---|
Effects of fasudil hydrochloride on cerebral blood flow in patients with chronic cerebral infarction.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aged; Blood Pressure; Calcium Channel Blockers; Cereb | 1993 |
Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Results of a prospective placebo-controlled double-blind trial.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Aged; Calcium; Cerebral Infarction; Double-Bli | 1992 |
8 other studies available for fasudil and Anterior Choroidal Artery Infarction
| Article | Year |
|---|---|
Real-world data of clazosentan in combination therapy for aneurysmal subarachnoid hemorrhage: a multicenter retrospective cohort study.
Topics: Aged; Brain Ischemia; Cerebral Infarction; Female; Humans; Middle Aged; Retrospective Studies; Subar | 2023 |
Combination of constraint-induced movement therapy with fasudil amplifies neurogenesis after focal cerebral ischemia/reperfusion in rats.
Topics: Animals; Brain Ischemia; Bromodeoxyuridine; Cerebral Infarction; Neurogenesis; Nogo Proteins; Rats; | 2022 |
Inhibition of Rho-kinase protects cerebral barrier from ischaemia-evoked injury through modulations of endothelial cell oxidative stress and tight junctions.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Animals; Astrocytes; Blood-Brain Barrier; Blo | 2014 |
Demonstration of elevation and localization of Rho-kinase activity in the brain of a rat model of cerebral infarction.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Activating Transcription Factor 3; Amides; Animals; B | 2008 |
Fasudil and ozagrel in combination show neuroprotective effects on cerebral infarction after murine middle cerebral artery occlusion.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cells, Cultured; Cerebral Infarction; Dose-R | 2011 |
Wide therapeutic time window for Rho-kinase inhibition therapy in ischemic brain damage in a rat cerebral thrombosis model.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Antipyrine; Blood Flow Velocity; Brain Ische | 2008 |
Pretreatment of transient focal cerebral ischemia in rats with the calcium antagonist AT877.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blood Pressure; Calcium; Cerebral Arteries; | 1994 |
Neuroprotection by intrathecal application of liposome-entrapped fasudil in a rat model of ischemia.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Brain Damage, Chronic; Brain Ischemia; Cereb | 2001 |